Daily Study

A lower session: SPY −0.35%, QQQ −0.32%

Three screens filtered 1,886 US stocks down to 12 names on this page: the top and the bottom of each ordering. 11 of 12 closed lower and 1 higher; small caps (IWM) moved −1.65%.

SPY−0.35%
S&P 500 ETF757.16
QQQ−0.32%
Nasdaq 100 ETF688.50
IWM−1.65%
Russell 2000 ETF278.42
DIA−0.38%
Dow 30 ETF522.46
names screened
1,886
studied in depth
145
on this page
12
screens
3

A record of what moved, not a recommendation.Prices: Alpaca IEX feed · Financials: SEC EDGAR XBRLMethodologyDisclaimer

Each screen starts from a broad filter of US stocks; the candidates are then ordered by a combined fundamentals-and-trend read. The page shows the names at the top and at the bottom of that order, so you see both ends of the same filter, not a pick list. Open any case study for the session, the three-month trend and the latest SEC financials. IEX volume is only the share traded on IEX, so it is compared with its own 20-day average.

Learn more: Top and Bottom of the Screen: An Ordering, Not a Verdict · Where the Numbers Come From: IEX Prices and SEC Filings · Reading the Cash Flow Statement · Return on Equity and Leverage

495matched the screen
60studied in depth
4on this page

Top of the screen

CRCT

Cricut Inc

8.49−4.4%
TechnologyComputer Hardware
3 months+54.1%
52-week range52w low80%high
RSI (14)67
Session
below VWAP 8.630.94× avg vol
Moving averages
above 50dabove 200d
View CRCT chart on TradingView Affiliate
Case study: why CRCT is on this page

Top of this screen: profitable last fiscal year; revenue -0.5% YoY; above its 200-day average; +54.1% over 3 months.

Close 8.49: −4.4% vs previous closeSession (open→close): −4.2%

Session: day range 8.48–8.87, VWAP 8.63 (below VWAP), IEX volume 0.94× its 20-day average. Trend: +54.1% over three months, 80% of the way up its 52-week range, RSI(14) 67, above its 50-day and above its 200-day average.

Intraday chart of CRCT on 2026-11-12
Session (intraday)
Three-month daily chart of CRCT
Three months (daily)
Revenue (latest FY)
$708.8M
Net income (latest FY)
$76.7M
Cash
$174.6M

Prices: Alpaca IEX feed · Financials: SEC EDGAR XBRL · Primary source: Cricut Inc filings on SEC EDGAR

EVC

Entravision Communications Corp

9.43−5.4%
Communication ServicesAdvertising Agencies
3 months+6.0%
52-week range52w low62%high
RSI (14)71
Session
below VWAP 9.581.04× avg vol
Moving averages
above 50dabove 200d
View EVC chart on TradingView Affiliate
Case study: why EVC is on this page

Top of this screen: a net loss last fiscal year; revenue +22.6% YoY; above its 200-day average.

Close 9.43: −5.4% vs previous closeSession (open→close): −5.4%

Session: day range 9.38–10.02, VWAP 9.58 (below VWAP), IEX volume 1.04× its 20-day average. Trend: +6.0% over three months, 62% of the way up its 52-week range, RSI(14) 71, above its 50-day and above its 200-day average.

Intraday chart of EVC on 2026-11-12
Session (intraday)
Three-month daily chart of EVC
Three months (daily)
Revenue (latest FY)
$447.6M
Net income (latest FY)
−$79.2M
Cash
$87.3M

Prices: Alpaca IEX feed · Financials: SEC EDGAR XBRL · Primary source: Entravision Communications Corp filings on SEC EDGAR

Bottom of the screen

ARTV

Artiva Biotherapeutics Inc

3.98−2.2%
HealthcareBiotechnology
3 months−66.1%
52-week range52w low8%high
RSI (14)22
Session
at VWAP 3.991.43× avg vol
Moving averages
below 50dbelow 200d
View ARTV chart on TradingView Affiliate
Case study: why ARTV is on this page

Bottom of this screen: a net loss last fiscal year; revenue -100.0% YoY; below its 200-day average; near its 52-week low; -66.1% over 3 months.

Close 3.98: −2.2% vs previous closeSession (open→close): −2.6%

Session: day range 3.94–4.09, VWAP 3.99 (at VWAP), IEX volume 1.43× its 20-day average. Trend: −66.1% over three months, 8% of the way up its 52-week range, RSI(14) 22, below its 50-day and below its 200-day average.

Intraday chart of ARTV on 2026-11-12
Session (intraday)
Three-month daily chart of ARTV
Three months (daily)
Revenue (latest FY)
$0
Net income (latest FY)
−$83.9M
Cash
$61.2M

Prices: Alpaca IEX feed · Financials: SEC EDGAR XBRL · Primary source: Artiva Biotherapeutics Inc filings on SEC EDGAR

PROK

ProKidney Corp

1.15+2.2%
HealthcareBiotechnology
3 months−18.4%
52-week range52w low14%high
RSI (14)38
Session
above VWAP 1.121.18× avg vol
Moving averages
below 50dbelow 200d
View PROK chart on TradingView Affiliate
Case study: why PROK is on this page

Bottom of this screen: a net loss last fiscal year; revenue +1075.0% YoY; below its 200-day average; -18.4% over 3 months.

Close 1.15: +2.2% vs previous closeSession (open→close): +3.6%

Session: day range 1.08–1.18, VWAP 1.12 (above VWAP), IEX volume 1.18× its 20-day average. Trend: −18.4% over three months, 14% of the way up its 52-week range, RSI(14) 38, below its 50-day and below its 200-day average.

Intraday chart of PROK on 2026-11-12
Session (intraday)
Three-month daily chart of PROK
Three months (daily)
Revenue (latest FY)
$893.0K
Net income (latest FY)
−$69.0M
Cash
$81.4M

Prices: Alpaca IEX feed · Financials: SEC EDGAR XBRL · Primary source: ProKidney Corp filings on SEC EDGAR

1,366matched the screen
60studied in depth
4on this page

Top of the screen

GEN

Gen Digital Inc

29.70−3.1%
TechnologySoftware - Infrastructure
3 months+8.4%
52-week range52w low86%high
RSI (14)63
Session
below VWAP 29.941.24× avg vol
Moving averages
above 50dabove 200d
View GEN chart on TradingView Affiliate
Case study: why GEN is on this page

Top of this screen: profitable last fiscal year; revenue +27.1% YoY; above its 200-day average.

Close 29.70: −3.1% vs previous closeSession (open→close): −2.5%

Session: day range 29.67–30.74, VWAP 29.94 (below VWAP), IEX volume 1.24× its 20-day average. Trend: +8.4% over three months, 86% of the way up its 52-week range, RSI(14) 63, above its 50-day and above its 200-day average.

Intraday chart of GEN on 2026-11-12
Session (intraday)
Three-month daily chart of GEN
Three months (daily)
Revenue (latest FY)
$5.00B
Net income (latest FY)
$973.0M
Cash
$589.0M

Prices: Alpaca IEX feed · Financials: SEC EDGAR XBRL · Primary source: Gen Digital Inc filings on SEC EDGAR

FULT

Fulton Financial Corp

23.84−0.6%
FinancialBanks - Regional
3 months−2.5%
52-week range52w low83%high
RSI (14)56
Session
at VWAP 23.830.51× avg vol
Moving averages
above 50dabove 200d
View FULT chart on TradingView Affiliate
Case study: why FULT is on this page

Top of this screen: profitable last fiscal year; revenue -6.5% YoY; above its 200-day average.

Close 23.84: −0.6% vs previous closeSession (open→close): −0.3%

Session: day range 23.75–23.94, VWAP 23.83 (at VWAP), IEX volume 0.51× its 20-day average. Trend: −2.5% over three months, 83% of the way up its 52-week range, RSI(14) 56, above its 50-day and above its 200-day average.

Intraday chart of FULT on 2026-11-12
Session (intraday)
Three-month daily chart of FULT
Three months (daily)
Revenue (latest FY)
$276.8M
Net income (latest FY)
$391.6M
Cash
$1.11B

Prices: Alpaca IEX feed · Financials: SEC EDGAR XBRL · Primary source: Fulton Financial Corp filings on SEC EDGAR

Bottom of the screen

IONS

Ionis Pharmaceuticals Inc

27.31−3.6%
HealthcareBiotechnology
3 months−53.4%
52-week range52w low0%high
RSI (14)17
Session
below VWAP 27.602.18× avg vol
Moving averages
below 50dbelow 200d
View IONS chart on TradingView Affiliate
Case study: why IONS is on this page

Bottom of this screen: a net loss last fiscal year; revenue +33.8% YoY; below its 200-day average; near its 52-week low; -53.4% over 3 months.

Close 27.31: −3.6% vs previous closeSession (open→close): −3.8%

Session: day range 27.29–28.53, VWAP 27.60 (below VWAP), IEX volume 2.18× its 20-day average. Trend: −53.4% over three months, 0% of the way up its 52-week range, RSI(14) 17, below its 50-day and below its 200-day average.

Intraday chart of IONS on 2026-11-12
Session (intraday)
Three-month daily chart of IONS
Three months (daily)
Revenue (latest FY)
$943.7M
Net income (latest FY)
−$381.4M
Cash
$296.3M

Prices: Alpaca IEX feed · Financials: SEC EDGAR XBRL · Primary source: Ionis Pharmaceuticals Inc filings on SEC EDGAR

GPCR

Structure Therapeutics Inc ADR

19.77−5.8%
HealthcareBiotechnology
3 months−63.3%
52-week range52w low1%high
RSI (14)32
Session
below VWAP 20.060.77× avg vol
Moving averages
below 50dbelow 200d
View GPCR chart on TradingView Affiliate
Case study: why GPCR is on this page

Bottom of this screen: a net loss last fiscal year; below its 200-day average; near its 52-week low; -63.3% over 3 months.

Close 19.77: −5.8% vs previous closeSession (open→close): −2.1%

Session: day range 19.66–20.92, VWAP 20.06 (below VWAP), IEX volume 0.77× its 20-day average. Trend: −63.3% over three months, 1% of the way up its 52-week range, RSI(14) 32, below its 50-day and below its 200-day average.

Intraday chart of GPCR on 2026-11-12
Session (intraday)
Three-month daily chart of GPCR
Three months (daily)
Revenue (latest FY)
n/a
Net income (latest FY)
−$141.2M
Cash
$222.0M

Prices: Alpaca IEX feed · Financials: SEC EDGAR XBRL · Primary source: Structure Therapeutics Inc ADR filings on SEC EDGAR

25matched the screen
25studied in depth
4on this page

Top of the screen

AAPL

Apple Inc

354.85−0.3%
TechnologyConsumer Electronics
3 months+16.1%
52-week range52w low96%high
RSI (14)60
Session
below VWAP 356.690.86× avg vol
Moving averages
above 50dabove 200d
View AAPL chart on TradingView Affiliate
Case study: why AAPL is on this page

Top of this screen: profitable last fiscal year; revenue +15.1% YoY; above its 200-day average; near its 52-week high; +16.1% over 3 months.

Close 354.85: −0.3% vs previous closeSession (open→close): −0.9%

Session: day range 354.43–359.33, VWAP 356.69 (below VWAP), IEX volume 0.86× its 20-day average. Trend: +16.1% over three months, 96% of the way up its 52-week range, RSI(14) 60, above its 50-day and above its 200-day average.

Intraday chart of AAPL on 2026-11-12
Session (intraday)
Three-month daily chart of AAPL
Three months (daily)
Revenue (latest FY)
$478.83B
Net income (latest FY)
$132.18B
Cash
$36.30B

Prices: Alpaca IEX feed · Financials: SEC EDGAR XBRL · Primary source: Apple Inc filings on SEC EDGAR

IDXX

Idexx Laboratories Inc

698.02−0.6%
HealthcareDiagnostics & Research
3 months+27.8%
52-week range52w low74%high
RSI (14)70
Session
below VWAP 702.420.60× avg vol
Moving averages
above 50dabove 200d
View IDXX chart on TradingView Affiliate
Case study: why IDXX is on this page

Top of this screen: profitable last fiscal year; revenue +10.4% YoY; above its 200-day average; +27.8% over 3 months.

Close 698.02: −0.6% vs previous closeSession (open→close): −1.8%

Session: day range 697.86–710.87, VWAP 702.42 (below VWAP), IEX volume 0.60× its 20-day average. Trend: +27.8% over three months, 74% of the way up its 52-week range, RSI(14) 70, above its 50-day and above its 200-day average.

Intraday chart of IDXX on 2026-11-12
Session (intraday)
Three-month daily chart of IDXX
Three months (daily)
Revenue (latest FY)
$4.30B
Net income (latest FY)
$1.06B
Cash
$197.5M

Prices: Alpaca IEX feed · Financials: SEC EDGAR XBRL · Primary source: Idexx Laboratories Inc filings on SEC EDGAR

Bottom of the screen

ALNY

Alnylam Pharmaceuticals Inc

156.62−2.0%
HealthcareBiotechnology
3 months−30.3%
52-week range52w low2%high
RSI (14)27
Session
below VWAP 158.410.78× avg vol
Moving averages
below 50dbelow 200d
View ALNY chart on TradingView Affiliate
Case study: why ALNY is on this page

Bottom of this screen: profitable last fiscal year; revenue +65.2% YoY; below its 200-day average; near its 52-week low; -30.3% over 3 months.

Close 156.62: −2.0% vs previous closeSession (open→close): −2.2%

Session: day range 156.62–162.06, VWAP 158.41 (below VWAP), IEX volume 0.78× its 20-day average. Trend: −30.3% over three months, 2% of the way up its 52-week range, RSI(14) 27, below its 50-day and below its 200-day average.

Intraday chart of ALNY on 2026-11-12
Session (intraday)
Three-month daily chart of ALNY
Three months (daily)
Revenue (latest FY)
$3.71B
Net income (latest FY)
$313.7M
Cash
$1.75B

Prices: Alpaca IEX feed · Financials: SEC EDGAR XBRL · Primary source: Alnylam Pharmaceuticals Inc filings on SEC EDGAR

NVDA

NVIDIA Corp

166.07−4.5%
TechnologySemiconductors
3 months−26.2%
52-week range52w low18%high
RSI (14)26
Session
above VWAP 162.433.37× avg vol
Moving averages
below 50dbelow 200d
View NVDA chart on TradingView Affiliate
Case study: why NVDA is on this page

Bottom of this screen: profitable last fiscal year; revenue +65.5% YoY; below its 200-day average; -26.2% over 3 months.

Close 166.07: −4.5% vs previous closeSession (open→close): +10.0%

Session: day range 148.80–167.14, VWAP 162.43 (above VWAP), IEX volume 3.37× its 20-day average. Trend: −26.2% over three months, 18% of the way up its 52-week range, RSI(14) 26, below its 50-day and below its 200-day average.

Intraday chart of NVDA on 2026-11-12
Session (intraday)
Three-month daily chart of NVDA
Three months (daily)
Revenue (latest FY)
$215.94B
Net income (latest FY)
$120.07B
Cash
$22.44B

Prices: Alpaca IEX feed · Financials: SEC EDGAR XBRL · Primary source: NVIDIA Corp filings on SEC EDGAR

The charts use the candlestick, VWAP and moving-average reading taught in our free courses. To pull up any of these tickers yourself, TradingView’s free plan covers it. Affiliate link: we may earn a commission if you subscribe, at no extra cost to you.

Reminder: nothing on this page is investment advice. These names appear because of where they landed in the screen, not because of any view on where the price goes next. Past performance does not indicate future results. See the Disclaimer.